XML 46 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Research and development expense
 12 Months Ended
Dec. 31, 2017
Research and development expense Disclosure [Abstract]  
Research and Development expense Disclosure [Text Block]
15.
Research and development expense:
 
In June 2015, the Company entered into a license and supply agreement with SteadyMed Ltd. for the distribution rights to TREVYENT® that included an upfront payment of $3,000 upon execution of the agreement which was recorded in R&D expense.